ABSTRACT: The effect of omeprazole on oral and intravenous (iv) RS-methadone pharmacokinetics and pharmacodynamics was studied in awake, freely moving rats, which were divided in four groups: oral RS-methadone (3 mg/kg) was given (a) to a control group (CO oral ) (n ¼ 65) and (b) to an omeprazole pretreated group (OP oral ) (n ¼ 77), and iv RS-methadone (0.35 mg/kg) was administered (c) to a control group (CO iv ) (n ¼ 86) and (d) to an omeprazole pretreated group (OP iv ) (n ¼ 86). Omeprazole (2 mg/kg) was given iv 2 h before RS-methadone. Plasma concentrations of RSmethadone (Cp) were determined by high-performance liquid chromatography and analgesic response by tail flick for 0-180 min (oral) and 0-120 min (iv). RS-Methadone rate of absorption (mean AE SE) was faster in OP oral (k 01 ¼ 0.31 AE 0.04 min À1 ) than in CO oral (k 01 ¼ 0.05 AE 0.007 min À1 ), consequently plasma peak concentrations (C max ) were greater (197.41 AE 33.70 ng/mL versus 83.54 AE 7.97 ng/mL) and the time to reach C max (t max ) was shorter (11.23 AE 1.32 min versus 39.18 AE 1.74 min). Mean area under the Cptime curve (AUC 0-1 ) and hence bioavailability of oral RS-methadone were increased by omeprazole without significant changes in the elimination. Omeprazole did not affect the pharmacokinetics of iv RS-methadone. The changes of the analgesic effect of RSmethadone as a function of time were similar in all four groups. In the CO oral group, Cp and analgesic effect were defined by the E max model. The relationship between Cp and drug effect in the OP oral group showed a counterclockwise hysteresis (k e0 of 0.018 AE 0.006 min
INTRODUCTION
Methadone is an opiate used orally 1,2 as substitution therapy for patients addicted to heroin 3 and also as an analgesic in patients with chronic pain. 4, 5 Patients treated with standard doses of methadone frequently complain of discomfort, pain, or some signs of withdrawal in maintenance programs, which is usually attributed to variability in individual pharmacokinetics (PK) such as absorption, metabolism, protein binding, and elimination. 6 Additionally, there are individuals that, despite having adequate plasma levels of methadone, (i.e. normal PK) do not respond adequately. This interindividual variability in the response can be attributed to the disease or to co-administration of other drugs. [3] [4] [5] [6] [7] [8] Methadone is a lipophilic basic drug with a pKa of 9.2, administered orally as a racemic mixture. Most available information on methadone PK properties has been generated in studies in which this mixture has been used. Like the majority of basic drugs administered orally, methadone is absorbed mainly in the small intestine where the pH is close to [5] [6] . A small fraction of the dose of methadone could also be absorbed in the stomach depending on the pH conditions. Interindividual differences in gastric pH could influence the plasma concentrations of a weak base. 9 In humans, oral bioavailability of methadone averages 80% of the dose (range 41-99% 8, 10, 11 ) , suggesting that absorption is a source of variability. Biotransformation of methadone is mainly mediated by CYP3A4, an enzyme sensitive to physiological changes, diet, and induction/inhibition by other drugs. Other isoforms of cytochrome P450 such as CYP2C9 and CYP2C19 contribute to methadone biotransformation but to a lesser extent. 12 Interindividual variability in the expression of these enzymes is another factor causing PK variability. Urinary excretion accounts for 24% of the dose, and changes in urinary pH may add another factor of variability. 8 Omeprazole irreversibly inhibits the H þ /K þ -ATPase proton pump so it modifies gastric pH and, consequently, it can also alter the absorption of drugs. It has been shown that after high oral doses of methadone (5 mg/kg) to the rat, intravenous (iv) omeprazole increases plasma levels of methadone and causes a respiratory depression. 13 The aims of the present study were to further investigate the methadone-omeprazole interaction assessing simultaneously the kinetics and the dynamics of methadone [PK/pharmacodynamics (PD)] using analgesic doses in the rat.
EXPERIMENTAL Animals and Surgical Procedures

Intragastric pH Measurement
Female Sprague-Dawley rats (n ¼ 12, 220-250 g) were divided into two groups to measure the effect of omeprazole on gastric pH. One group of rats (n ¼ 6) received omeprazole iv (2 mg/kg) and the remaining rats were used as controls.
After 24 h of fasting, rats were anesthetized with urethane (1 mg/kg), the pylorus was tied, and 2 mL of distilled water was administered orally with a syringe connected to a gastric intubator. A few minutes later, 2 mL of gastric juice was collected for pH measurement with a pH indicator tape. A similar procedure was used with rats receiving omeprazole, with the exception that 2 h before the oral administration of distilled water, omeprazole was administered iv.
RS-Methadone Administration by iv Route
Female Sprague-Dawley rats (n ¼ 172, 225-250 g) were divided into (a) control rats (n ¼ 86) who received RS-methadone iv (0.35 mg/kg) (CO iv ) to assess the time course of RS-methadone plasma concentration (Cp) (n ¼ 66) or its effect (n ¼ 20), and (b) rats (n ¼ 86) pretreated with omeprazole (2 mg/kg iv) 2 h before the iv injection of RSmethadone (OP iv ), to document the time course of RS-methadone Cp (n ¼ 66), and the time course of the effect (n ¼ 20).
The day before the experiment, rats were lightly anesthetized with ether, and a polyethylene catheter (i.d. 0.3 mm, 10 cm length; Vygon, Ecouen, France) was implanted in the right carotid artery for blood-sample collection. Another catheter was inserted into the right jugular vein for the iv administration of methadone in both groups and omeprazole in the pretreated group. All catheters were filled with a solution containing Nalco 0.9% and 1% heparin (50 IU/mL; Chiesi Wassermann SA, Barcelona, Spain). The catheters were tunnelled under the skin of the animal and externalized on the dorsal surface of the neck. After surgery, rats remained under fasting conditions but with ad libitum access to water (for 24 h).
RS-Methadone Administration by Oral Route
Female Sprague-Dawley rats (n ¼ 142) weighing between 210 and 250 g were used to assess RSmethadone plasma concentration (Cp)-analgesic effect relationship (n ¼ 104) and the time course of the effect (n ¼ 38). The rats were divided into two groups: (a) control rats (n ¼ 65) who received RSmethadone orally (3 mg/kg) to assess the Cp-effect relationship (n ¼ 40), or the time course of the effect (n ¼ 25); (b) rats (n ¼ 77) pretreated with omeprazole (2 mg/kg iv) 2 h before oral RS-methadone (OP oral ) to document the Cp-effect relationship (n ¼ 64), and the time course of the effect (n ¼ 13).
The animal preparation procedure was similar to the one described for the iv administration of methadone with the difference that in both groups, control (CO oral ) and omeprazole treatment (OP oral ), an intubator was used for oral administration of methadone.
The Sprague-Dawley rats were supplied by the University of the Basque Country. The experimental protocol was approved by the Committee on Animal Experimentation of the University of the Basque Country. Animals were randomly distributed into groups of six and were kept under a controlled temperature of 208C and humidity of 70% with a normal 12 h light/dark cycle (8:00 am to 8:00 pm) for 1 week before any experiment was initiated. Food and water were available ad libitum.
Drug Administration and Collection of Samples for the Methadone Assay
Intravenous Administration of RS-Methadone
Rats of the control group (CO iv ) (n ¼ 66) and those receiving omeprazole (OP iv ) (n ¼ 66) were administered 0.35 mg/kg iv of RS-methadone in 30 s dissolved in saline. Omeprazole (2 mg/kg in saline solution) was given iv to OP iv , 2 h before the administration of RS-methadone.
Blood samples (2.5 mL from each rat) were drawn at 1, 2, 3, 4, 5, 10, 15, 30, 60, 90, and 120 min after RS-methadone administration, each time point including six animals. Blood was placed in heparinized tubes, centrifuged at 2500 rpm for 15 min at 378C, and the plasma kept frozen at À 208C until assay of RS-methadone.
Oral Administration of RS-Methadone
Rats (n ¼ 104) received 3 mg/kg of RS-methadone (2 mg/mL in water) through the gastric intubator. This dose of RS-methadone was found to elicit analgesia with minor respiratory effects. 13 Each animal received weight-corrected volume (&0.35 mL) of solution to individualize the dose. Distilled water was added to reach a final volume of 2 mL. Omeprazole (2 mg/kg in saline solution) was given iv, 2 h before oral administration of methadone (OP oral , n ¼ 64), and the remaining rats were used as controls (CO oral , n ¼ 40).
Blood samples (2.5 mL from each rat) were withdrawn at 5, 10, 15, 30, 45, 60, 120, and 180 min after RS-methadone administration from the rats of the OP oral group, and at 15, 30, 45, 60, 90, 120, and 180 min after RS-methadone administration from the rats of the CO oral group. Each time point represents the average of six to eight rats. Blood was collected in heparinized tubes, centrifuged at 2500 rpm for 15 min at 378C, and the plasma kept at À 208C until assay of RS-methadone.
RS-Methadone Assay
Plasma RS-methadone levels were determined by high-performance liquid chromatography (HPLC) according to the method described by Wolff et al. 14 with minor modifications. 15 The HPLC equipment included an HPLC pump (type 422; Kontron Instruments, Bilbao, Spain) and an ultraviolet detector (Waters 486, Milford, MA). The separation was performed in a 5-mm silica column (Apex I, 25 Â0.45 cm; Teknocroma, Barcelona, Spain) and a Corasil Type II silica pre-column (Teknocroma). RS-Methadone and the internal standard (benzhexol) were determined by a UV detector at a wavelength of 215 nm.
One milliliter of plasma was mixed with 10 mL of a solution containing the internal standard (1 mg/mL) and 0.5 mL of sodium carbonate buffer (1 M, pH 10) to which 5 mL of n-butyl chloride saturated in water was added, for the extraction of RS-methadone. The mixture was mechanically shaken for 15 min and then centrifuged at 4000 rpm at 48C for 10 min. The n-butyl chloride upper layer was vacuum aspirated and placed in a 5-mL glass tube and evaporated at 508C (AES 1000, Speed Vac Concentrator, Savant, Spain). The solid residue was dissolved in 110 mL of methanol, and 100 mL was injected into the chromatograph system. The mobile phase was methanol/1,2-dichloroethane/isopropanol/ammonium perchloride aqueous solution (100 g/L) in the proportion 90.5:5:4:0.5 v/v, at a flow rate of 2 mL/min. The sensitivity of the analytical procedure is 5 ng/mL of RS-methadone and is linear over the range of 5 to 350 ng/mL. The mean within and between-assay precision and extraction efficiencies were [mean (CV)] 91% (6.1%), 92.4% (3.5%), and 87.1% (5.4%), respectively (n ¼ 3).
Measurement of RS-Methadone Analgesic Effect
The tail-flick method 16 was used to assess the analgesic effect of RS-methadone. Animals responded to a heat stimulus by moving their tail away from the focus of the stimulus, thereby exposing a photocell located below the tail. The reaction time was automatically recorded. The intensity of the heat was adjusted so that the basal measurements were 2-5 s; animals with longer baseline latencies than 5 s were excluded. A maximal cut-off time of 10 s was used to prevent tissue damage. RS-Methadone analgesic effect was expressed as percentage of the maximum possible (observed) response (%MPR) and was calculated as follows: 
Oral Administration of RS-Methadone
The analgesic effect of oral RS-methadone was assessed in 142 rats. In 104 of them, the analgesic effect was assessed along with the collection of a blood sample for assay of RS-methadone. The remaining rats (n ¼ 38) were used to document the time course of analgesic effect, from 0 to 180 min in each animal. The rats of the latter group were segregated in CO oral (n ¼ 25) and OP oral (n ¼ 13) subgroups. Analgesia was assessed at 5, 10, 15, 30, 45, 60, 90, 120, and 180 min, in the OP oral group, and at 15, 30, 45, 60, 90, 120, and 180 min, in the CO oral group, after the administration of RS-methadone Chemicals RS-Methadone chlorhydrate was supplied by Alcaliber (Madrid, Spain). Omeprazole was purchased from Schering-Plough (Losec 1 40 mg iv infusion; Madrid, Spain). Benzhexol chlorhydrate (dl-trihexyphenidyl) was obtained from Sigma (Madrid, Spain). All of the remaining reactants and solvents were of analytical grade.
PK Analysis
Intravenous Administration of RS-Methadone
The profile of RS-methadone concentration as a function of time following the iv administration was described by a two-compartmental model, for both the control and omeprazole pretreated groups:
where Cp(t) is RS-methadone plasma concentration at time t, a is the distribution rate constant, b is the disposition rate constant of the terminal exponential phase, and A and B are the intercept parameters. PK parameter estimates were obtained by fitting RS-methadone concentration observations to eq. 2 using the software package WINNONLIN (version 3.0; Pharsight, Inc., Mountain View, CA). Model selection was based on the Akaike Information Criterion, as well as by inspection of residual plots. A proportional error model was used for the concentration (iteratively re-weighted least squares). The compartmental transfer rates k 12 , k 21 , k 10 were also estimated as well as systemic CL and central volume of distribution (Vc). These parameters were used to simulate RS-methadone concentrations in the CO iv and OP iv groups where only the time course of effect was measured. Volume of distribution at steady state (Vss) and area under the plasma versus time-concentration curve from 0 to infinite time (AUC 0-1 ) and maximum concentration (C max ) were also calculated by WINNONLIN.
Oral Administration of RS-Methadone
Plasma concentrations of this particular oral RSmethadone dataset were parsimoniously fitted by a mono-compartmental first-order absorption model defined as:
where Cp(t) is the concentration at time t, D is the dose, V/F is the apparent volume of distribution, and k 01 and k 10 are the absorption and elimination rate constants, respectively. Oral systemic bioavailability (F) of RS-methadone was calculated from the RS-methadone plasma AUC 0-1 after iv and oral administration.
Volume of distribution of RS-methadone (V) in the absence or presence of omeprazole, was calculated by multiplying the estimated V/F value by the systemic bioavailability (F). RS-Methadone systemic plasma clearance (CL) was calculated multiplying V by k 10 .
Pharmacodynamic Analysis
Intravenous Administration of RS-Methadone
The relationship between analgesic response as a function of simulated plasma concentration (Cp), for both CO iv and OP iv groups, was described using the E max sigmoid model:
where E is the effect elicited by RS-methadone Cp, E max is the maximum effect, EC 50 is the concentration generating 50% of E max , and g is the Hill sigmoidicity measure of the E versus Cp curve. The parameters, EC 50 and g, were estimated with WINNONLIN and an additive error model (ordinary least squares).
Oral Administration of RS-Methadone
The analgesic response versus plasma concentrations after oral RS-methadone dose in controls (CO oral ) were parsimoniously described, for this particular dataset, using a ''simple'' E max model (i.e., with a g ¼ 1). The above sigmoid and simple E max models apply when the plot of E as a function of Cp depicts a one-to-one relationship. However, in the group of rats receiving RS-methadone orally and omeprazole (OP oral ), the analgesic effect as a function of RS-methadone plasma concentrations relationship displayed a counterclockwise hysteresis. A PK/PD link model was applied to relate the appropriate concentration with the effect. A semiparametric approach 17 (Cp observations rather than PK parameter-based simulations are fitted) was used to assess the changes of the concentration as a function of time in the compartment effect through the relation:
where Ce is the concentration in the effect compartment or biophase, and k e0 is the rate constant for drug removal from the effect compartment, characterizing the temporal aspects of equilibration between an effect and the plasma concentration.
Statistical Analyses
The observed values of effect and pH were expressed as mean AE standard error of the mean (SE 
RESULTS
Intragastric pH
The administration of omeprazole significantly elevated intragastric pH values, at 2 h, from an average of 3.8 AE 0.12 (control) to 5.75 AE 0.2 ( p < 0.001).
PK
Intravenous Administration of RS-Methadone
Individual RS-Methadone plasma concentrations as a function of time, as well as predicted mean plasma concentrations are depicted in Figure 1 . Compared with control rats, the decline of RSmethadone plasma concentrations as a function of time was not affected by the administration of omeprazole. The administration of omeprazole 2 h before iv RS-methadone did not modify the PK parameters of RS-methadone (Table 1) .
Oral Administration of RS-Methadone
RS-Methadone plasma concentrations as a function of time, as well as predicted plasma concentrations are depicted in Figure 2 . The absorption rate of oral RS-methadone was enhanced by pretreatment with omeprazole (k 01 ¼ 0.31 min
À1
versus 0.05 min À1 ) ( Table 2) . As a consequence, RS-methadone mean maximum plasma concentrations (C max ) was increased by 136% ( p < 0.01), and the time to reach C max (t max ) was decreased by 71% ( p < 0.001). In addition, in rats pretreated with omeprazole, mean RS-methadone AUC 0-1 was 65% greater than AUC 0-1 values estimated in the control group. However, both groups had similar k 10 values.
Compared with control rats, systemic bioavailability (F) following oral administration, RSmethadone was increased in rats pretreated with omeprazole, i.e., 28% and 51%, respectively. RSMethadone apparent volume of distribution and clearance, corrected by F, were not affected by the pretreatment with omeprazole (Table 2) .
PD: Effect Versus Time
Intravenous Administration of RS-Methadone Figure 3 shows the time course of the mean (AE SEM) analgesic effect in both groups from 0 to 120 min. The administration of omeprazole did not alter the time course of the analgesic effect in either group (CO iv , n ¼ 20, and OP iv , n ¼ 20).
Oral Administration of RS-Methadone
Rats with complete effect-time serial measurements were used to assess the analgesic response to RS-methadone, in control (CO oral , n ¼ 25) and omeprazole pretreated groups (OP oral , n ¼ 13). Figure 4 shows the time course of the mean (AE SEM) analgesic effect in both groups (0 to 180 min) and shows that analgesia was slightly higher in pretreated animals but with no pointto-point statistical differences between groups ( p > 0.05). The administration of omeprazole alone did not change the baseline pain scores.
PD: Effect Versus Concentration
Intravenous Administration of RS-Methadone
The analgesic effect as a function of simulated RSmethadone Cp was best described by an E max sigmoid model for both CO iv and OP iv groups (Fig. 5) . The PD parameters of iv RS-methadone were not influenced by the administration of omeprazole (Table 3) .
Oral Administration of RS-Methadone
To analyze the relationship between the analgesic response and RS-methadone plasma concentrations, only rats with Cp-effect paired measurements at single time points were used (n ¼ 6-8 rats per point). In rats of the CO oral group, the relationship between analgesic effect and Cp was defined by a hyperbola, which was described by the simple E max model (eq. 4; g ¼ 1). E max being 100%, the EC 50 of RS-methadone was 69.1 AE 12.0 ng/mL. In the OP oral group, when the analgesic effect as a function of RS-methadone plasma concentrations, was plotted in a time-ordered manner, a counterclockwise hysteresis was depicted (Fig. 6) . The hysteresis was reduced through the relation of eq. 5 so the effect as a function of effect-site RSmethadone concentration (Ce) was optimally fitted by the E max model. For E max ¼ 100, the rate constant for drug removal from the effect compartment (k e0 ) was 0.018 AE 0.006 min À1 and the ECe 50 (same as EC 50 at equilibrium) of RSmethadone was 127.2 AE 26.0 ng/mL (Table 4) .
It is interesting to note that the analgesic response of RS-methadone was route-dependent. Effectively, in control rats, for a similar plasma concentration, RS-methadone analgesic response was greater when RS-methadone was administered iv (Fig. 7) . That is, the efficiency and the potency of iv RS-methadone are greater than the estimated after oral administration of RS-methadone.
DISCUSSION
The potential of omeprazole to interfere with the oral bioavailability of aspirin, 18 methadone, 13 trovafloxacin, 19 digoxin, 20 theophylline, 21 and nifedipine 22 has been well documented in animals and humans. In most of these cases, the changes in bioavailability were attributed to changes in absorption related to an increase in intragastric pH. The latter may lead to a decrease in the absorption of drugs that are weak acids, while enhancing the absorption of weak bases. However, it has been demonstrated in vitro that omeprazole may inhibit the activity of cytochrome CYP450 isoforms, specifically CYP2C19, CYP3A, and CYP2C9. There are omeprazole interactions involving inhibition of CYP2C19 in vivo (e.g., diazepam), but only weak interactions occur with the other isoforms. [23] [24] [25] RS-Methadone is metabolized mainly by CYP3A and omeprazole (100 mmolar) is known to inhibit the metabolism of methadone ''in vitro. '' 12 In the present study, omeprazole increased the pH of the rat stomach and, as a consequence, the rate of absorption as well as the bioavailability of RS-methadone administered orally were increased without changes in the disposition parameters (k 10 , V, and CL). When RS-methadone was administered iv, the presence of omeprazole did not alter the distribution or the clearance of RS-methadone. In agreement with previous reports, 14, 26, 27 the present results show that in the rat, RS-methadone bioavailability is low and because the rat's small intestine contains large amounts of CYP3A, presystemic metabolism within the intestine may contribute to the low RS-methadone bioavailability. Therefore, in the absence of changes in systemic clearance, an increase in RS-methadone bioavailability could be attributed to a decrease in its intestinal extraction. Hence, the mechanisms underlying the omeprazole RS-methadone interaction can be associated with changes in RS-methadone (30) absorption or in presystemic metabolism, or a combination of both factors. RS-Methadone is a synthetic narcotic and analgesic used clinically as a racemic mixture of R-(þ)-methadone and S-(À)-methadone. R-(þ)-methadone has twice the affinity for m1 and m2 opioid receptors than the racemic mixture, whereas S-(À)-methadone essentially does not possess opioid properties. 28 The present results demonstrate that in control rats, RS-methadone analgesic response depends on the route of administration. The rightward shift of the effect versus concentration curve, after an oral dose of RS-methadone, indicates that higher concentrations are needed to produce an effect similar to that elicited by an iv dose, i.e., the EC 50 is 17 ng/ mL for iv RS-methadone and 69 ng/mL for oral RS-methadone. These results suggest that RSmethadone is subjected to stereoselective presystemic metabolism so, when racemic methadone is given orally, the ratio of active to inactive [R-(þ)-/ S-(À)-] enantiomers of methadone may be lower than when methadone is injected iv. A similar phenomenon has been reported for verapamil. After oral administration and for the same total concentration, the ratio of inactive R-(þ)-to active S-(À)-verapamil is two to three times greater than when verapamil is administered iv and its negative dromotropic effect on AV conduction is reduced. 29 The route-dependent effect of verapamil has been attributed to a stereoselective first pass metabolism for the active form, yielding an RS-verapamil total concentration in plasma enriched with the inactive form.
Omeprazole increases the bioavailability of oral RS-methadone by 82% without increasing its analgesic effect. It is noteworthy that the effect-concentration relationship of oral RSmethadone in absence of omeprazole elicits a hyperbola, defined by the E max model. In the presence of omeprazole, the plot of the analgesic effect as a function of oral RS-methadone plasma concentrations depicts a counterclockwise hysteresis loop. This phenomenon indicates a complex relationship between plasma concentrations and effects that may result from (a) a temporal equilibration delay due to perfusion, capillary diffusion or binding to proteins in plasma and tissue, (b) receptor affinity alterations (association/dissociation rates), (c) a complex response involving the induction of protein synthesis, (d) the presence of active metabolites, or (e) the presence of stereoisomers with different kinetics and pharmacological activity. The fact that after iv RSmethadone, omeprazole did not modify the effectconcentration relationship, suggests that the EFFECT OF OMEPRAZOLE ON RS-METHADONE PK AND PD hysteresis generated by oral RS-methadone is not secondary to (a), (b), (c), and (d). Therefore, we must assume that the RS-methadone-omeprazole interaction is secondary to a stereoselective change in RS-methadone enantiomers, i.e., increase in S-(À)-methadone or slow conversion of
Because the RS-methadone-omeprazole interaction is not apparent after iv RS-methadone, we must assume that the interaction occurs in the gastrointestinal tract. Supporting such hypothesis, it has been shown that in presence of bicarbonate, used as an alkalizing agent, the bioavailability of oral RS-methadone is greatly increased, and that the effect-plasma concentration relationship of oral RS-methadone is converted into a counterclockwise hysteresis. 13 The PK of RS-methadone enantiomers in humans are stereospecific, particularly with respect to plasma protein binding, distribution, and elimination. 30, 31 Specifically, the free fraction in plasma of the active enantiomer, R-(þ)-methadone, is 42% greater than that of S-(À)-methadone, and as a result R-(þ)-methadone volume of distribution and clearance are greater than S-(À)-methadone distribution and clearance. In general, stereoselectivity is not an issue for the absorption of the vast majority of drugs because absorption is usually done by passive diffusion. However, the aqueous solubility and crystal form of the racemates can be different from those of the individual isomers, and this may lead to differences in the dissolution rates at the site of administration. [32] [33] [34] Nonstereoselective differences in RS-methadone absorption have been reported; nevertheless, oral administration of RS-methadone to patients shows an important interindividual variability in the stereoselective disposition of the enantiomers, i.e., the R/S ratio in plasma varies from 0.63 to 2.40. 35 Here, pretreatment with omeprazole increased plasma concentrations (AUC) of RS-methadone administered orally (65%) without increasing its analgesic response. This observation may be tentatively explained by assuming that omeprazole increased the bioavailability of S-(À)-methadone, the inactive enantiomer. Supporting this hypothesis is also the fact that omeprazole reduced the EC 50 of RS-methadone from 69.1 to 127.2 ng/mL. An increase in S-(À)-methadone may occur whenever (a) the absorption of RSmethadone is pH dependent, in such a way that S-(À)-methadone is unstable at acidic pH and its stability increases in the presence of omeprazole, or (b) omeprazole selectively diminishes intestinal presystemic metabolism of S-(À)-methadone. Recent unpublished results obtained in our laboratory show that after the administration of only the S-(À)-methadone isomer and following the same protocol as in this study, omeprazole produced a 92% increase in AUC, whereas the analgesic effect was negligible in both control and pretreated groups.
The administration of drugs in their racemic form entails stereospecific kinetics and dynamics, adverse drugs effects, and drug-drug interactions. 34, 36 Stereospecific drug-drug interactions are rather frequent at the phase of biotransformation, although there is scarce information about stereospecific absorption of drugs or of interactions at this level. For example, S-ketorolac rate of absorption is slower than that of R-ketorolac.
37
The interaction of omeprazole with RS-warfarin may be of interest because of its resemblance with the results of the present study. In individuals receiving oral RS-warfarin, omeprazole increases RS-warfarin plasma concentrations because of an increase in R-warfarin concentration (the lessactive enantiomer) with no apparent effect on S-warfarin plasma concentration (the active enantiomer), changes that do not entail alterations in the coagulation time. 38, 39 Although it has been postulated as mechanism of action a preferential inhibition of R-warfarin presystemic metabolism, an alternative explanation would be based on the fact that RS-warfarin appears better absorbed at high gastric pH. 40, 41 This study supports the possibility that omeprazole-RS-methadone interaction takes place in the stomach; however we cannot discard an alternative explanation: i.e., that the interaction occurs at the level of the small intestine. Effectively, RS-methadone metabolism is mediated by CYP2C19, 2C9, and 3A1. Epithelial cells of the small intestine, in humans, express CYP2C and 3A 12, 42 enzymes that may be competitively inhibited by omeprazole because these enzymes contribute to omeprazole metabolism. CYP3A is also present in small bowel enterocytes in the rat and it has been shown (''in vitro'') that they are involved in intestinal metabolism of methadone, 43 in which case, omeprazole ought to cause a greater inhibition of S-(À)-methadone biotransformation than of R-(þ)-methadone. This hypothesis is supported by the fact that in the intestine and in the liver, the rate of metabolism of RSmethadone 30 and RS-propranolol 44 is stereoselective and so may be its inhibition.
It is concluded that omeprazole increases plasma concentrations of oral RS-methadone without incrementing its analgesic response, thus altering the concentration-effect relationship. This omeprazole-RS-methadone interaction could be a source of interindividual variability in RSmethadone disposition, and could cause difficulties in the design of dosage regimens based on plasma levels, particularly in multi-medicated patients.
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